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Abstract Aquaculture, the fastest growing food-produc-
ing sector, now accounts for nearly 50 % of the world’s
food fish (FAO in The state of world fisheries and aqua-
culture. FAO, Rome, 2010). The global aquaculture pro-
duction of food fish reached 62.7 million tonnes in 2011
and is continuously increasing with an estimated produc-
tion of food fish of 66.5 million tonnes in 2012 (a 9.4 %
increase in 1 year, FAO, www.fao.org/fishery/topic/16140).
Aquaculture is not only important for sustainable protein-
based food fish production but also for the aquaculture
industry and economy worldwide. Disease prevention is
the key issue to maintain a sustainable development of
aquaculture. Widespread use of antibiotics in aquaculture
has led to the development of antibiotic-resistant bacteria
and the accumulation of antibiotics in the environment,
resulting in water and soil pollution. Thus, vaccination is
the most effective and environmentally-friendly approach
to combat diseases in aquaculture to manage fish health.
Furthermore, when compared to [760 vaccines against
human diseases, there are only about 30 fish vaccines
commercially available, suggesting the urgent need for
development and cost-effective production of fish vaccines
for managing fish health, especially in the fast growing fish
farming in Asia where profit is minimal and therefore given
high priority. Plant genetic engineering has made signifi-
cant contributions to production of biotech crops for food,
feed, valuable recombinant proteins etc. in the past three
decades. The use of plants for vaccine production offers
several advantages such as low cost, safety and easy scal-
ing up. To date a large number of plant-derived vaccines,
antibodies and therapeutic proteins have been produced for
human health, of which a few have been made commer-
cially available. However, the development of animal
vaccines in plants, especially fish vaccines by genetic
engineering, has not yet been addressed. Therefore, there is
a need to exploit plant biotechnology for cost effective fish
vaccine development in plants, in particular, edible crops
for oral fish vaccines. This review provides insight into (1)
the current status of fish vaccine and vaccination in aqua-
culture, (2) plant biotechnology and edible crops for fish
vaccines for oral administration, (3) regulatory constraints
and (4) conclusions and future perspectives.
Keywords Aquaculture  Food security  Fish vaccine 
Plant genetic engineering  Regulatory constraints
Introduction
Fish is an excellent animal protein source and contains a
wide range of essential human nutrients. Up to 80 % of the
world’s fish production is used for human consumption,
indicating the important role of aquaculture for food
security. Fisheries and aquaculture play also an important
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role in the livelihoods of millions of people worldwide
from the small-scale inland fishermen who harvest fishes
from lakes and rivers to the industrial scale fish farming.
Thus, sustainable fish farming contributes considerably to
food security (www.fao.org).
Aquaculture is the farming of aquatic organisms
including fish, crustaceans, molluscs and aquatic plants.
Fisheries and aquaculture make important contributions to
the human population as protein sources. The global
aquaculture production of food fish reached 62.7 million
tonnes in 2011 and is continuously increasing with an
estimated production of food fish of 66.5 million tonnes in
2012 (a 9.4 % increase in 1 year, FAO, www.fao.org/
fishery/topic/16140). In the past five decades, the world fish
supply has rapidly increased with an average growth rate of
3.2 % per year and constitutes an important source of
nutrition and animal protein for humans (FAO 2012;
http://www.fao.org, Fig. 1). This is particularly the case in
Asia, where approximately 90 % of the total global aqua-
culture products comes from. Among the Asian countries,
China alone produces ca. 70 % of the world total volume
of aquaculture products and has become the largest pro-
ducer of farmed seafood in the world, with an increase of
490 % since 1978 (Ellis 2009). It is estimated that in the
next decade total production from both capture and aqua-
culture will exceed that of beef, pork or poultry. Due to
higher demand for fish, world fisheries and aquaculture
production are projected to reach about 172 million tonnes
in 2021, of which aquaculture is projected to reach about
79 million tonnes, rising by 33 % over the period
2012–2021 (FAO 2012, http://www.fao.org). This boom in
aquaculture will help to achieve certain millennium
development goals either directly (e.g. eradication of
extreme poverty and hunger) or indirectly (e.g. substantial
improvement in economies). However, aquaculture is as
vulnerable to adverse impacts of disease and unfavourable
environmental conditions as is farming of other animals.
Disease outbreaks in recent years have affected Atlantic
salmon, oyster and marine shrimp farming in several
countries of the world, resulting in partial or sometimes
total loss of production. In 2010, aquaculture in China
suffered production losses of 1.7 million tonnes caused by
natural disasters, diseases and pollution. Disease outbreaks
virtually wiped out marine shrimp farming production in
Mozambique in 2011 (FAO 2012). Fish diseases not only
pose a threat to the aquaculture industry but also to human
livelihood and health. Apart from zoonoses, use of certain
chemicals and antibiotics for fish health also pose certain
risks to the environment, human health and food security
(for a review see Sapkota et al. 2008). Management of
aquatic animal health is therefore an important issue for
food security, to protect livelihoods of millions of people,
the aquaculture industry and the environment.
History and current status of fish vaccines
and vaccination approaches
Compared with human vaccine history starting from the
discovery of vaccination by Edward Jenner in 1796 leading
to production of [760 vaccines for protecting human
health, fish vaccine development has a very short history
with roughly 40 years since the 1970s. It took over three
decades from the first scientific report describing fish
vaccination using an inactivated orally administrated Aer-
omonas salmonicida vaccine. The first licensed fish vac-
cine was made commercially available in 1976 (Evelyn
1997). The first fish vaccine was produced from killed
Yersinia ruckeri, and used to protect fishes against enteric
redmouth (ERM) by oral administration. Soon after the
release of ERM oral fish vaccine, a new vaccine for Vibrio
anguillarum became available in the USA with vaccination
via immersion. These were followed with the release of
Furunculosis vaccines in Europe in the 1980s. To date,
there are no more than 30 commercial vaccines for the
prevention of a wide range of fish diseases, with a few
more under development (Smith 2008). The economic,
environmental and animal welfare benefits have been
recognised as a result of the widespread use of vaccines in
the aquaculture industry. The potential from vaccines for
lower mortality, improved growth efficiency and higher
yields is now a critical factor in disease management pro-
grammes in aquaculture. To date, commercially used fish
vaccines are mainly: killed vaccines such as inactivated
virus or bacterial antigens, subunit vaccines and recombi-
nant vaccines with humoral (antibody) responses, or live,
attenuated and DNA vaccines for cytotoxic T cell response
(Plant and LaPatra 2011, http://www.pharmaq.no).
At present, three main delivery approaches are used for
fish vaccination: (1) injection vaccination, (2) oral vacci-
nation, and (3) immersion vaccination (including bath and
spray vaccination). The advantages and drawbacks of each
vaccination method are summarized in Table 1.
Fig. 1 Worldwide fish production in five decades. Data source
(www.fao.org/fishery/aquaculture)
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Given that none of the vaccination approaches are uni-
versal, choice of vaccination method will be largely
determined by the type and size of the fish, protection
required, pathogen’s nature, type of immune reaction
required and the vaccine’s nature (single or multivalent), as
well as the cost which is essential for fish industry and
small fish farmers in the developing countries. New fish
vaccine development and the production of fish vaccines
require that vaccines must be effective and suitable for
large-scale production at low cost, making the vaccines
available and affordable to the aquaculture fish industry
and small fish farmers in the developing countries.
Facing economic pressure in the aquaculture industry,
intensive fish farming has increased the spread of diseases
and parasites. To manage the problem, a large amount of
antibiotics are applied in aquaculture with the hope of
enhancing production and improving the socioeconomic
profile of the fish farmers in the developing countries.
The presence of antibiotic compounds in the aquatic
environment has resulted in environmental pollution,
especially water pollution. It leads also to the development
of antibiotic-resistant bacteria making bacterial disease
control in aquaculture a challenging task. Increased mor-
tality of Penaeus monodon larvae due to antibiotic-resistant
Vibrio harveyi infection has been reported (Karunasagar
et al. 1994). Furthermore, infectious diseases in aquacul-
ture are caused not only by bacteria but also viruses, fungi
and parasites. Thus, vaccination is the most effective way
to protect fishes and to manage aquaculture in an envi-
ronmentally friendly manner. Application of plant bio-
technological tools for fish vaccine development is of
importance for aquaculture as the fish vaccines have to be
produced at a low cost and for easy scaling up, making
them accessible and affordable for not only the aquaculture
industry worldwide, but in particular for improvement of
the conditions for small fish farmers in the developing
countries.
Exploitation of plant genetic engineering
for low cost production of fish vaccines
Fish have a functional immune system similar to mammals
(innate and adaptive) and the advancement and experiences
of plant biotechnology in vaccine development for humans
and other mammals could be of importance for the devel-
opment of fish vaccines. The use of plants for development
and production of recombinant vaccines offers several
advantages. Plant-based systems are more economical as
plants can be grown on a larger scale than in other systems.
Low cost is no doubt one of the most important issues in
the future development of fish vaccines. Plants also possess
the ability to carry out post-translational modifications
similar to naturally occurring systems. The plant-based
systems bypass the safety concerns inherent in live virus
vaccines.
Table 1 Fish vaccination
methods and their advantages
and drawbacks [adapted from











Most common method of vaccine delivery
in fish
Effective in generating both humoral
(antibody) and cellular cytotoxic
response
Protection is of long duration
Not feasible for fishes under 20 g
Stressful for the fish due to handling and
anesthetizing
Labour intensive






Ideal delivery method via feed
Easiest, no technical skill required
No handling stress for the fish
Protection from the digestive system
No additional labour cost
No investment on instrument required
Feasible for mass vaccination of all sizes
of fishes
Large amount of antigen needed
Poor and short-term protection (except
for Y. ruckeri and V. anguillarum).






Simple and suitable for mass vaccination
Less stress for the fish than injection
Lower labour costs
Less risk to vaccination team
Not suitable for all farmed fishes
Stressful for the fish because of netting
and transportation prior to spray
vaccination
Large amount of vaccine required in the
case of the bath method
Lower level of protection and duration
of immunity
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To date, three main plant-based techniques have been
used for the expression of a large number of vaccine
antigens, monoclonal antibodies (mAbs) and other bio-
pharmaceuticals in plants. These are (1) stable expression
of transgenes in the nuclear genome of transgenic plants or
cell culture, (2) stable expression of transgenes in the
plastid genome of transplastomic plants by plastid genetic
engineering and (3) transient expression of transgenes in
plants. A number of reviews have covered all the three
methodologies (Streatfield 2007; Daniell et al. 2009;
Clarke and Daniell 2011; Lo¨ssl and Waheed 2011; Maliga
and Bock 2011; Yusibov et al. 2011). Each system has its
advantages and limitations and the method of choice is
largely depending on what kind of fish vaccines are to be
expressed, as briefly described in Table 2. To date, both
food and non-food crops (especially tobacco plant) have
been used for the development of a number of animal
vaccines, such as a poultry vaccine against Newcastle
disease (Hahn et al. 2007; Yang et al. 2007; Li et al. 2007;
Go´mez et al.2009; Van Eck and Keen 2009; Wu et al.
2009: for reviews see Floss et al. 2007 and He et al. 2008),
rabies (Ashraf et al. 2005; Loza-Rubio et al. 2008; Roy
et al. 2010; Loza-Rubio et al. 2012), Porcine reproductive
and respiratory syndrome virus (PRRSV) and Porcine post-
weaning diarrhea in piglets (Chen and Liu 2011; Kolotilin
et al. 2012). The vaccine against Newcastle disease was the
first plant-made animal vaccine receiving regulatory
approval from the US Department of Agriculture (USDA)




Moreover, studies on plant-based animal vaccines for
protecting mink, dogs, and cats are reported (Dalsgaard
et al. 1997; Molina et al. 2004). Molina et al. (2004, 2005)
demonstrated high-level expression of a tobacco chloro-
plast-derived vaccine based on a B cell epitope from canine
parvovirus and the induction of neutralizing antibodies.
Three recent reviews by Floss et al. (2007), Joensuu et al.
(2008) and Rybicki (2010) have provided an overview of
production of veterinary vaccines in plants. However,
plants as expression systems for production of fish vaccines
are lagging behind compared with the plant-made veteri-
nary vaccines for non-aquatic (land-based) animals. Based
on the special advantages of oral vaccination in aquacul-
ture, Companjen et al. (2005) successfully expressed the
non-toxic part of the E. coli heat-labile enterotoxin LTB
fused with a viral peptide or GFP in potato tuber for oral
immunization and induction of specific humoral immune
response in carp upon feed-mediated administration. This
study demonstrated the feasibility of producing fish vac-
cines for oral vaccination in an edible crop and the tech-
nology shall be explored further. To boost an efficient
delivery of plant-made oral fish vaccine to immune-com-
petent cells in the gut mucosa, a carrier molecule i.e. LTB
in the study was fused to the oral vaccine antigens to
stimulate the uptake and immune response upon feed-
mediated oral immunization.. Another attempt is our own
ongoing research in production of a fish vaccine in tobacco
chloroplasts against viral nervous necrosis (VNN) caused
by Nodavirus (Clarke et al. ongoing research). VNN affects
farmed fish such as turbot, Atlantic halibut and Atlantic
cod, as well as wild fish (Grotmol et al. 1995, 1997;
Munday et al. 2002; Sommerset et al. 2005). The risk of
VNN spreading from escapes of farmed fish to wild indi-
cates the significance of the development of a cost effective
and safe vaccine against VNN infection. The economic
importance of such a vaccine for farmed fish is self-evi-
dent. In this study, transplastomic tobacco lines expressing
RNA2 as the antigen candidate were produced and are
currently subject to various molecular analyses (Clarke
et al. unpublished results).
Engineering edible crops for the development
of fish vaccines for oral immunization
Edible crops are ideal green factories for the production of
therapeutic proteins and vaccines for oral immunization. In
aquaculture, among the current fish vaccination methods
shown in Table 1, a fish vaccine produced in an edible crop
(or microalgae) for oral immunization is undoubtedly
advantageous because oral vaccination of fish is an easy,
labour-saving and stress free method which is suitable for
all fishes independent of the fish size.
Despite the advantages and potentials of plant vaccine
production systems for animal health including aquatic
animals, there are only a few studies reporting the veteri-
nary vaccine antigens expressed in edible crops, only one
case for fish vaccine produced in potato for oral delivery
via feed suggesting strongly that research effort is needed
to develop and advance the research field in the future for
effective management of fish health by cost effective plant-
made oral fish vaccines. Successful management of fish
health will directly contribute to sustainable food fish
production in the future. To date, lettuce and potato tubers
have been used for the development of plant-based animal
vaccines (Companjen et al. 2005; Go´mez et al. 2008;
Matsui et al. 2009). So far, there is no report describing
fish vaccine antigens expressed in edible crops by
plastid genome engineering, despite the technology for
plastid engineering of edible crops such as lettuce, tomato,
potato, cabbage etc. having been developed and used to
express a number of foreign proteins (Kanamoto et al.
2006; Ruf et al. 2001; Ruhlman et al. 2007, 2010; Daniell
et al. 2009; Cardi et al. 2010; Clarke and Daniell 2011;
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Davoodi-Semiromi et al. 2010; Kanagaraj et al. 2011;
Boyhan and Daniell 2010; Lakshmi et al. 2013). Based on
the experience from human vaccines produced in edible
crops, the development of fish vaccines in edible crops for
oral vaccination will be a reality in the future.
Regulatory constraints
It was 30 years ago when the first genetically modified (GM)
plant was produced by using Agrobacterium tumefaciens—
mediated genetic transformation (for historical perspective
see Bevan et al. 1983; Fraley et al. 1983; Herrera-Estrella
et al. 1983 and review by Vasil 2008). Thirteen years
later, the first GM crop was commercialized in 1996
(http://www.isaaa.org). Since then, there has been a fast
development with first, second and third generations of
GM plants produced worldwide. Despite the encouraging
news that the global status of commercialized biotech crops
has reached 170.3 million hectares globally in 2012
(http://www.isaaa.org), at an annual growth rate of 6 %, up
10.3 million from 160 million hectares in 2011 and with
significant benefits for farmers, the regulatory constraints
are a well-known hurdle for commercialization of biotech
crops in many countries, especially in Europe. Molecular
farming using plants or plant cell lines as a green factory to
produce vaccines and biopharmaceuticals has also made
considerable progress with commercially released plant-
made therapeutic proteins, and a number of vaccines and
therapeutic proteins are undergoing clinical trials or are in
Table 2 Plant expression systems and their future application in fish vaccine development








Fast and easy scaling up
Feasible for Nicotiana
benthamiana and tobacco plants
Limitations:
Not applicable in edible crops
Not feasible Feasible and desirable Feasible and desirable
Plastid engineering
Advantages
High level expression of foreign proteins
([70 % of total soluble proteins), suitable
for production in large quantity
Biosafety via maternal inheritance and
inducible promoter like T7
Methods established in both food (lettuce,
soybean, tomato, potato, cabbage etc.)
and non-food crops (tobacco, poplar etc.)
Multiple genes (up to 8 genes) can be
expressed in a single event
Cost effective
Limitations
Not applicable for glycoproteins
Protein stability at room temperature
Feasible and desirable for
both single and
multivalent vaccines
Feasible and suitable for
both single and
multivalent vaccines
Feasible and desirable for
both single and
multivalent vaccines
An example: fish vaccine
antigen expressed in
tobacco chloroplasts




Methods established in a




Low expression level of recombinant proteins
Biosafety concern as pollen contains transgene
Transgene segregation when via seed propagation
Feasible but less desirable
due to the low expression
level
Report: Antigen fused with
LTB and expressed in
potato showed humoral
immune response in carp
gut (Companjen et al.
2005)
Feasible and suitable Feasible but less desirable
due to the low expression
level
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the pipeline to be approved (Yusibov et al. 2011;
http://www.genengnews.com/gen-news-highlights/); how-
ever, it has encountered the same regulatory constraints as
other GM crops. Under the current regulatory requirements,
it’s estimated that it takes on average 7-10 million euros to
approve a GM crop for cultivation (Paul et al. 2011).
Current USDA-APHIS regulatory requirements are based
on the use of plant pathogens (Agrobacterium) for trans-
formation or use of plant pathogenic sequences (Agrobac-
terium genome sequence or plant viral genome sequence,
especially the CaMV promoter). So, in order to minimize
regulatory costs, one could use the chloroplast transforma-
tion approach for molecular pharming, which doesn’t use
any plant pathogenic sequences. This approach should sig-
nificantly minimize the cost of regulatory approval for field
studies. Indeed, plant-made pharmaceuticals engineered via
the chloroplast genome have been tested in the field several
years ago (Arlen et al. 2007). One among the most important
regulatory hurdles for molecular pharming is transgene
containment. Early plant-made vaccine companies were
shut down by USDA-APHIS for contamination of food/feed
grains by corn seeds expressing human therapeutic proteins
(e.g. Prodigene). Such regulatory challenges could therefore
be avoided by not expressing vaccines in seeds. For exam-
ple, expressing vaccine antigens in leaves facilitates their
harvest before appearance of any reproductive structures,
thereby avoiding contamination via pollen or seeds (Daniell
et al. 2009). In addition, expressing vaccine antigens via the
chloroplast genome facilitates maternal inheritance of
transgenes and minimizes or eliminates out-cross via pollen
(Daniell 2007; Daniell et al. 1998).
Another important cost in regulatory approval is the need
for release into the environment, requiring large acreage of
field studies in different geographical locations. However,
for molecular pharming using the chloroplast transformation
approach, high levels of expression result in minimal acre-
age. For example, one acre of cultivation could produce up
to 360 million doses of vaccines (Koya et al. 2005; Watson
et al. 2004). Thus, the production could be contained within
the greenhouse, eliminating the need for field release.
So far, none of the plant-made vaccines has been
approved for oral delivery, an essential requirement for low
cost fish vaccine. Bioencapsulation protects vaccine anti-
gens expressed within plant cells, and they are released in
the gut by the action of microbes colonizing the gut (Li-
maye et al. 2006; Kwon et al. 2013a, b; Arlen et al. 2008;
Davoodi-Semiromi et al. 2010). However, neither the
transient viral expression system that infects plant cells nor
low level expression of stable nuclear expression is ideal
for oral delivery of vaccines. However, several oral vac-
cines expressed via the chloroplast genome have been
shown to be effective against pathogen or toxin challenge
(Davoodi-Semiromi et al. 2010; Arlen et al. 2008) or
immune disorders (Ruhlman et al. 2007; Verma et al.
2010). In addition, regulatory agencies require demon-
stration of long-term stability of vaccine at room temper-
ature. Such stability has been shown by storage of
lyophilized leaf materials for several months or years
expressing human therapeutic proteins (Kwon et al. 2013a,
b), vaccine antigens or autoantigens (Lakshmi et al. 2013,
Kwon et al. 2013a, b). Moreover, the process of lyophili-
zation eliminates microbes that colonize plants, an impor-
tant regulatory requirement (Kwon et al. 2013a). In
addition, the concentration of vaccine antigens is increased
15–25 fold, significantly reducing the amount of plant
materials required for effective vaccination (Kwon et al.
2013a). The aforementioned advantages make the lettuce
chloroplast system ideal for oral vaccines and several
human therapeutic proteins have been expressed at high
levels in lettuce chloroplasts (Davoodi-Semiromi et al.
2010; Kanagaraj et al., 2011; Boyhan and Daniell 2010;
Lakshmi et al. 2013; Ruhlman et al. 2007, 2010). Future
studies should therefore focus on edible leaves rather than
tobacco that has nicotine and other alkaloids, not permitted
by any of the global regulatory agencies.
Conclusions
With the challenges of the growing world population, food
security demand and unpredictable climate change, aquatic
fish health and management have become a global concern
which affects protein-based food security, the environment,
and the aquaculture industry and millions of fish farmers in
the developing countries. To use biotechnological tools to
manipulate plants for low-cost and safe vaccine production
for farmed fish is a research field which needs to be
advanced and strengthened. This review has addressed
these issues and provided an overview of the current situ-
ation in fish health management, the status of fish vaccine
and vaccinations, as well as how to explore plant genetic
engineering for the development and cost-effective pro-
duction of fish vaccines. The utilization of plants for low-
cost and large quantity production of fish vaccines with
oral immunization by plant genetic engineering, especially
plastid genetic engineering of edible crops, should be
emphasized. Oral vaccination is of special importance for
fishes weighing less than 20 g. To promote an efficient
delivery of plant-made oral fish vaccine to immune-com-
petent cells in the gut mucosa, a carrier molecule such as
LTB or CTB should be fused to the oral vaccine antigens to
stimulate the uptake and immune response upon feed-
mediated oral immunization. Altogether, there is an urgent
need for the research community to advance and imple-
ment plant genetic engineering of edible crops for pro-
duction of fish vaccines for oral vaccination via feed.
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